Casgevy (exagamglogene autotemcel) is now approved in the U.S. to treat children as young as 2 with sickle cell disease (SCD) and recurrent vaso-occlusive crises (VOCs). The U.S. Food and Drug Administration (FDA) initially approved the Vertex Pharmaceuticals’ gene-editing therapy in 2023 for SCD patients ages 12 and older who…
Discussion
If you’re like me and have a good medical team, over time, you’ve likely grown attached to them. When you’re fortunate enough to have a competent and consistent team that genuinely cares about your health, those types of relationships matter in ways that go beyond doctor appointments. That type of…
Discussion
A low dose of Vascarta‘s VAS-101, a curcumin-based gel being developed for sickle cell disease (SCD), was well tolerated and showed early signs of reducing red blood cell sickling, pain, and fatigue when administered under the tongue in a small Phase 1 study. The Phase 1 trial was…
Discussion
Five years ago, I wasn’t sure I could do this. I remember staring at a blank screen and wondering whether I had anything worth saying. I knew what it felt like to live with sickle cell disease — the pain, the hospital admissions, the exhaustion, the grief. But writing…
Becoming educated and informed about sickle cell disease is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your sickle cell disease journey.
A stem cell transplant is the only potential cure for sickle cell disease, but there are a variety of other treatment approaches. Here you can find more information about current treatments as well as experimental therapies in the pipeline.
Get regular updates to your inbox.
